ArticleCancers2024
A Description and Safety Overview of Irreversible Electroporation for Prostate Tissue Ablation in Intermediate-Risk Prostate Cancer Patients: Preliminary Results from the PRESERVE Trial.
Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04972097 (Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue in an Intermediate-Risk Patient Population), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue in an Intermediate-Risk Patient Population
Who cites it
12 citing papers in PubMed.
- Salvage prostate therapies for local pelvic recurrence after primary radiation for prostate cancer.BJUI compass · 2026Article
- Irreversible Electroporation for Tonsillar Ablation in Adults.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026Article
- Results from the PRESERVE trial: an editorial commentary.Translational andrology and urology · 2026Article
- Irreversible Electroporation for the Treatment of Pediatric Adenotonsillar Hypertrophy.Journal of clinical medicine · 2026Article
- Irreversible electroporation in focal therapy for prostate cancer: current status and future directions.Prostate international · 2026Review
- Integrated Diagnosis and Therapy Using Flexible Contact Electrodes: Low-Voltage Irreversible Electroporation and Quantitative Assessment of Therapeutic Efficacy.Annals of biomedical engineering · 2026Article
- Focal Therapy for Prostate Cancer: State of the Art, Physical Principles, Potentials, and Challenges.Cancers · 2026Review
- Dose Is a Critical Factor Affecting Treatment Volumes for Integrated Nanosecond Pulse Irreversible Electroporation (INSPIRE).IEEE transactions on bio-medical engineering · 2026Article
- Focal irreversible electroporation for the treatment of localised prostate cancer: a systematic review.Translational andrology and urology · 2025Review
- The growing armamentarium of image-guided tumor ablation in interventional oncology.Radiology advances · 2025Review
- Hydrodissection using 10% dextrose before focal therapy of prostate cancer: Initial experience.BJUI compass · 2025Article
- The use of focal therapy for the treatment of prostate cancer in Canada Where are we, how did we get here, and where are we going?Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
The PRESERVE study (NCT04972097) aims to evaluate the safety and effectiveness of the NanoKnife System to ablate prostate tissue in patients with intermediate-risk prostate cancer (PCa). The NanoKnife uses irreversible electroporation (IRE) to deliver high-voltage electrical pulses to change the permeability of cell membranes, leading to cell death. A total of 121 subjects with organ-confined PCa ≤ T2c, prostate-specific antigens (PSAs) ≤ 15 ng/mL, and a Gleason score of 3 + 4 or 4 + 3 underwent focal ablation of the index lesion. The primary endpoints included negative in-field biopsy and adverse event incidence, type, and severity through 12 months. At the time of analysis, the trial had completed accrual with preliminary follow-up available. Demographics, disease characteristics, procedural details, PSA responses, and adverse events (AEs) are presented. The median (IQR) age at screening was 67.0 (61.0-72.0) years and Gleason distribution 3 + 4 (80.2%) and 4 + 3 (19.8%). At 6 months, all patients with available data (n = 74) experienced a median (IQR) percent reduction in PSA of 67.6% (52.3-82.2%). Only ten subjects (8.3%) experienced a Grade 3 adverse event; five were procedure-related. No Grade ≥ 4 AEs were reported. This study supports prior findings that IRE prostate ablation with the NanoKnife System can be performed safely. Final results are required to fully assess oncological, functional, and safety outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.